Scarica l'app Stockscreener
30.95
0.26%
-0.08
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026 - TradingView
ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer - Stock Titan
ArriVent BioPharma reports $49.9 million Q2 net loss - Quiver Quantitative
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - The Manila Times
ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026 - Stock Titan
ArriVent Q2 net loss widens to $49.89 million; R&D expenses rise to $42.34 million - Bitget
ArriVent BioPharma (AVBP) Edges Higher, Holding Key Support at $29.44Time Weighted Price - Vinanet
ArriVent BioPharma (AVBP) Eases 0.55% to $30.84 as Shares Remain Range-BoundBull Flag - vinanet.vn
ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday - MarketBeat
Trading the Move, Not the Narrative: (AVBP) Edition - Stock Traders Daily
ArriVent BioPharma (AVBP) Surges 6.24% to $31.49 – Biotech Momentum IntensifiesGEX Level - vinanet.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vivo Capital LLC Takes $20.44 Million Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
141,814 Shares in ArriVent BioPharma, Inc. $AVBP Bought by ADAR1 Capital Management LLC - MarketBeat
Arrivent Biopharma Inc (AVBP) Cash Flow - TradingKey
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
AVBP|Arrivent Biopharma Inc|Price:30.140|Chg%:-1.590 - TradingKey
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arrivent Biopharma Inc (AVBP) Balance Sheet - TradingKey
AVBP|Arrivent Biopharma Inc|Price:31.730|Chg%:+0.190 - TradingKey
ArriVent BioPharma, Inc. Revenue Breakdown – NASDAQ:AVBP - TradingView
Arrivent Biopharma Inc (AVBP) Income Statement - TradingKey
AVBP|Arrivent Biopharma Inc|Price:32.020|Chg%:+0.480 - TradingKey
(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading 6.8% HigherHere's What Happened - MarketBeat
ArriVent BioPharma (AVBP) Edges Lower, Holding Above Key Support as Consolidation ContinuesLarge Cap Trends - dars.gov.et
ArriVent BioPharma (AVBP) Edges Lower, Testing Support Amid Biotech VolatilityDefined Outcome ETF - dars.gov.et
AVBP Q1 2026 Earnings: EPS Misses Estimates, Stock Gains on Strategic ProgressEarnings Turnaround - Vinanet
ArriVent BioPharma Q1 2026 Earnings: EPS Miss Reflects Increased R&D Spending; Shares Edge HigherCEO Earnings Statement - dars.gov.et
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target - TipRanks
AVBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AVBP Q1 2026 Earnings: EPS Miss Highlights Development Stage ChallengesEPS Growth Rate - DonanımHaber
ArriVent BioPharma (AVBP) Holds Near Support After Modest PullbackFear Greed Index - dars.gov.et
ArriVent BioPharma (AVBP) Edges Lower Amid Consolidation Near Key LevelsPCR Divergence - dars.gov.et
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):